Gilead announces interim Phase 2 data for idelalisib showing response in refractory indolent non-Hodgkin’s lymphoma
17 July 2013 | By Gilead Sciences
Results from Phase 2 study...
List view / Grid view
17 July 2013 | By Gilead Sciences
Results from Phase 2 study...
17 June 2013 | By Gilead Sciences, Inc.
Gilead Sciences announced interim results from a single-arm, open-label Phase 2 study evaluating idelalisib...
7 June 2013 | By Gilead Sciences
Gilead Sciences announced that the U.S. FDA has granted priority review...
28 May 2013 | By Gilead Sciences
Gilead Sciences announced that the European Commission has granted marketing authorization for Stribild®...
21 May 2013 | By Gilead Sciences
Gilead Sciences announced that the company’s MAA for sofosbuvir...
15 May 2013 | By Gilead Sciences
Gilead Sciences, Inc. announced results from a Phase 2 study...
2 May 2013 | By Gilead Sciences
Gilead Sciences announced plans to initiate a third Phase 3 clinical trial...
29 April 2013 | By Gilead Sciences
FDA states that it cannot approve the applications in their current forms...
23 April 2013 | By Gilead Sciences
Detailed results from four Phase 3 clinical trials...
8 April 2013 | By Gilead Sciences
Sofosbuvir, a once-daily oral nucleotide analogue for the treatment of chronic hepatitis C virus infection...
26 March 2013 | By Gilead Sciences
Gilead Sciences provided an update on ION-1...
22 March 2013 | By Gilead Sciences
Stribild® a once-daily integrase inhibitor-based single tablet regimen for the treatment of HIV-1 infection...
10 March 2013 | By Gilead Sciences
Gilead Sciences announced data from the Phase 4 TERISA study...
5 March 2013 | By Gilead Sciences
TAF-based regimen now in Phase 3 development...
19 February 2013 | By Gilead Sciences
Gilead and Teva Pharmaceuticals have reached an agreement in principle to settle the ongoing patent litigation...